Apr 24 |
Day One slips despite Ojemda approval as BofA says label “not a home run”
|
Apr 24 |
Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
|
Apr 23 |
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
|
Apr 23 |
Day One wins FDA nod for brain cancer therapy, Ojemda
|
Mar 15 |
Companies Like Day One Biopharmaceuticals (NASDAQ:DAWN) Are In A Position To Invest In Growth
|
Mar 13 |
13 Best Biotech Stocks To Buy Under $20
|
Feb 28 |
Day One Biopharmaceuticals Inc (DAWN) Reports Q4 and Full Year 2023 Financial Results
|
Feb 1 |
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
|
Jan 31 |
Dwayne 'The Rock' Johnson's net worth: How the new TKO Board Member built his wealth from $7
|
Jan 17 |
Day One Announces Two New Appointments to Board of Directors
|